Alexion Pharmaceuticals (ALXN) Receiving Somewhat Positive Media Coverage, Analysis Finds

A researcher working in a lab

65 investors sold all, 171 reduced holdings as ALXN ratio fall. 64 funds amassed holdings and 178 increased holdings. The quick ratio of 2.9 is a measure of how well a company can meet its short-term financial liabilities with quick assets (cash and cash equivalents, short-term marketable securities, and accounts receivable). Alexion Pharmaceuticals has a 52-week low of $120.71 and a 52-week high of $122.97.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, April 26th. Ftb Advisors has invested 0% of its portfolio in Alexion Pharmaceuticals, Inc. The Massachusetts-based Liberty Mutual Group Inc Asset has invested 0.03% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). British Columbia Invest Mngmt Corporation holds 103,254 shares. Goldman Sachs Group Inc owns 181,033 shares or 0% of their United States portfolio. Wms Prns Ltd Liability holds 2,275 shares. State Of Tennessee Treasury Department owns 595,919 shares for 0.32% of their portfolio. (NASDAQ:ALXN) for 263 shs. They expect $2.47 EPS, up 19.90% or $0.41 from last year's $2.06 per share. Vident Invest Advisory Llc stated it has 0.04% of its portfolio in Alexion Pharmaceuticals, Inc. The rating was maintained by Leerink Swann on Friday, February 9 with "Outperform". Taken from Pura Vida Investments latest Adv, the fund reported to have 13 full and part-time employees.

Since January 1, 0001, it had 1 buy, and 12 insider sales for $3.41 million activity. Goff Brian had sold 1,651 shs worth $192,028 on Tuesday, February 6. Franchini Indrani Lall also sold $169,696 worth of Alexion Pharmaceuticals, Inc. Also, Director Christopher J. Coughlin purchased 10,000 shares of the business's stock in a transaction that occurred on Monday, April 30th. Alexion Pharmaceuticals, given 6 buy-equivalent recommendations, 0 sells and 1 holds. (NASDAQ:ALXN) or 1,651 shares.

The company had seen its current volume reaching at 1.64 million shares in the last trade. 698 shares were sold by Wagner Heidi L, worth $83,305 on Tuesday, February 27.

Public Sector Pension Investment Board increased Alexion Pharmaceuticals Inc (ALXN) stake by 47.41% reported in 2017Q4 SEC filing. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company's stock valued at $109,000 after buying an additional 947 shares during the period. 204.38 million shares or 1.21% less from 206.89 million shares in 2017Q3 were reported.

The stock decreased 1.06% or $1.3 during the last trading session, reaching $121.55. Daily volume is the number of shares that are traded during one trading day. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 8.84% since May 16, 2017 and is downtrending. The stock underperformed the S&P 500 by 20.39%. Dupont Capital Management Corp purchased a new position in Alexion Pharmaceuticals during the 1st quarter valued at about $220,000.

Among 29 analysts covering Alexion Pharmaceuticals Inc.

Several research firms recently weighed in on ALXN. During the same quarter in the previous year, the company earned $1.38 EPS. ALXN's profit will be $327.08 million for 20.58 P/E if the $1.47 EPS becomes a reality. New York-based Tourbillon Lp has invested 2.65% in Alexion Pharmaceuticals, Inc.

RSP Permian, Inc. (RSPP) stock revealed 1.34% return for the recent month and disclosed 36.71% return in 3-month period. (ALXN) price hitting a mean target of $159.15 a share, meaning the stock still has potential that could lift the price another 30.93% Also, the recent close suggests the stock is underpriced by 51.38% compared to the most bullish target. More interesting news about Alexion Pharmaceuticals, Inc.

Gabriel Smith joined the, after more than 10 years of experience in writing financial and business news, most recently as Investment Editor and writer. Finally, BidaskClub upgraded shares of Alexion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, March 17th. Therefore 93% are positive. Jennison Assocs Lc reported 0.59% in Alexion Pharmaceuticals, Inc. The stock presently has a consensus rating of "Buy" and a consensus target price of $155.50. On Thursday, February 8 the rating was maintained by Stifel Nicolaus with "Buy". (NASDAQ:ALXN) rating on Tuesday, September 12. SunTrust maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned "Buy" rating by Citigroup. Piper Jaffray has "Buy" rating and $170.0 target.

Alexion Pharmaceuticals opened at $121.55 on Wednesday, reports. Robert W. Baird set a $160.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a "buy" rating in a research report on Thursday, March 15th. Finally, BMO Capital Markets boosted their price objective on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an "outperform" rating in a research note on Friday, February 9th. On Thursday, February 8 the rating was maintained by Jefferies with "Hold".

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Latest news

BMW previews autonomous iNext ahead of concept reveal later this year
Instead it will come with Level 3 capability that demands the driver monitor progress and be ready to takeover, if required. The company claims that the new flagship would incorporate all major strategic areas of innovation in a road-ready vehicle.

Somewhat Favorable News Coverage Somewhat Unlikely to Affect Caterpillar (CAT) Stock Price
After $0.70 actual EPS reported by Renasant Corporation for the previous quarter, Wall Street now forecasts 4.29% EPS growth. On Tuesday, April 24 the firm earned "Buy" rating by Goldman Sachs. (NYSE: CAT ) has "Hold" rating given by Robert W.

Diageo (LON:DGE) Has "Buy" Rating Reiterated at Citigroup
The average 12 month target price among brokerages that have covered the stock in the a year ago is GBX 2,621 ($36.56). This is indicating the analyst believes there is a potential upside of 5 .6% from today's opening price of 2699 GBX.

Teva Pharmaceutical Industries (TEVA) Receives "Hold" Rating from Morgan Stanley
This ratio also gives some idea of whether you're paying too much for what would be left if the company went bankrupt immediately. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, "The Little Book that Beats the Market".

FDA Calls Out Drug Makers That Improperly Block Generic Competition
Some of the products in the new list are indeed subject to those program limits - but some aren't at all, the FDA said. Gilead's had 10 complaints about its own hypertension product, Letairis, and gotten two letters.

Other news